Benzinga's Top Downgrades

Analysts at Credit Suisse downgraded Infinity Pharmaceuticals (NASDAQ: INFI ) from “outperform” to “neutral.” The target price for Infinity Pharmaceuticals is set to $20. Infinity's shares closed at $13.31 yesterday. Analysts at JMP Securities downgraded Progress Software (NASDAQ: PRGS ) from “market outperform” to “market perform.” Progress Software's